<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>; therefore it is a major focus in the development of novel anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> agents </plain></SENT>
<SENT sid="1" pm="."><plain>Hedyotis diffusa Willd has been used as a major component in several Chinese medicine formulas for the clinical treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>However, the precise mechanism of its anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity remains largely unclear </plain></SENT>
<SENT sid="3" pm="."><plain>Using a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, in the present study we evaluated the effect of the <z:chebi fb="37" ids="16236,44730">ethanol</z:chebi> extract of Hedyotis diffusa Willd (EEHDW) on <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo and investigated the underlying molecular mechanisms </plain></SENT>
<SENT sid="4" pm="."><plain>We found that EEHDW reduced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> weight, but had no effect on body <z:mp ids='MP_0005456'>weight gain</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> mice, demonstrating that EEHDW can inhibit <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> growth in vivo without apparent adverse effect </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, EEHDW treatment suppressed STAT3 phosphorylation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues, which in turn resulted in the promotion of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and inhibition of proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, EEHDW treatment altered the expression pattern of several important target genes of the STAT3 signaling pathway, i.e., decreased expression of Cyclin D1, CDK4 and Bcl-2 as well as up-regulated p21 and Bax </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that suppression of the STAT3 pathway might be one of the mechanisms by which EEHDW treats <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>